- RecruitingPHASE1, PHASE2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
This study is looking at a new medicine called ETX101 for babies and children with Dravet Syndrome. Researchers want to see if it's safe and helps reduce seizures. It includes different age groups, from 6 months up to 17 years.
For: Dravet SyndromeUnited States · Australia · United Kingdom - Active not recruitingPHASE1, PHASE2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
This study is looking at a new gene therapy, ETX101, for young children with a specific type of Dravet Syndrome. Doctors want to see if it's safe and helps reduce seizures in children aged 6 to 47 months.
For: Dravet SyndromeUnited Kingdom